摘要
心血管疾病 (CVD) 仍然是全球发病率和死亡率的主要原因。 CVD 包括各种危及生命的疾病,例如心肌梗塞、中风和外周动脉疾病。在这种情况下,动脉粥样硬化继续在这些疾病的发病机制中发挥主要作用。动脉粥样硬化源于一系列可改变和不可改变的风险因素,包括年龄、男性、家族史、肥胖、吸烟、糖尿病和高血压。最近的证据将动脉粥样硬化归类为一种潜伏性疾病,它影响所有大小的动脉,并倾向于出现血液供应减少或缺乏的动脉分支点。动脉粥样硬化不仅是一种脂质代谢紊乱,而且还是一种慢性炎症。本综述对动脉粥样硬化的潜在病理机制和目前应用的治疗干预措施进行了概要讨论。然后我们讨论经典的降脂疗法以及新发现的疗法。对于经典疗法,我们指出他汀类药物和依折麦布在降低血浆胆固醇水平方面的重要性,因为它们对胆固醇的合成、再摄取和肠道吸收有影响。我们还讨论了贝特类在调节脂质代谢和提高高密度与低密度脂蛋白比率方面的作用。本研究侧重于最近的分子和遗传干预,例如前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型 (PCSK9) 单克隆抗体、evinacumab 和 microRNA 抑制剂。还特别关注涉及这些疗法的临床试验。
关键词: 动脉粥样硬化、他汀类药物、贝特类药物、依折麦布、PCSK9 抑制剂、microRNA 抑制剂、动脉粥样硬化的单克隆抗体。
Current Medicinal Chemistry
Title:Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Volume: 28 Issue: 36
关键词: 动脉粥样硬化、他汀类药物、贝特类药物、依折麦布、PCSK9 抑制剂、microRNA 抑制剂、动脉粥样硬化的单克隆抗体。
摘要: Cardiovascular disease (CVD) remains the primary cause of global morbidity and mortality. CVD includes various life-threatening conditions such as myocardial infarction, stroke and peripheral arterial diseases. In this context, atherosclerosis continues to play the principal role in the pathogenesis of these conditions. Atherosclerosis emanates from a set of modifiable and non-modifiable risk factors that include age, male gender, family history, obesity, smoking, diabetes mellitus and hypertension. Recent evidence classifies atherosclerosis as a latent disease affecting all-sized arteries with a predilection for arterial branching points of decreased or absent blood supply. Atherosclerosis is not only a lipid metabolism disorder, but is also a chronic inflammatory one. This review providesa synoptic discussion of the underlying pathological mechanisms of atherosclerosis andthe currently applied therapeutic interventions. We then discuss the classical lipid-lowering therapies as well as the newly discovered therapies. For the classical therapies, we point out the importance of statins and ezetimibe in reducing plasma cholesterol levels by virtue of their effects on synthesis, reuptake and intestinal absorption of cholesterol. We also discuss the role of fibrates in modulating lipid metabolism and improving the ratio of high-density to low-density density lipoproteins. This study focuseson the more recent molecular and genetic interventions exemplified by proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, evinacumab, and microRNA inhibitors. Special attention is also given to clinical trials involving these therapies.
Export Options
About this article
Cite this article as:
Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies, Current Medicinal Chemistry 2021; 28 (36) . https://dx.doi.org/10.2174/0929867328666210222092628
DOI https://dx.doi.org/10.2174/0929867328666210222092628 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Rheumatoid Foot and Ankle Surgery
Current Rheumatology Reviews The Use of Radioactive Iodine in the Management of Hyperthyroidism in Children
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Induced pluripotent stem cell-derived mesenchymal stem cells: A leap toward personalized therapies.
Current Stem Cell Research & Therapy Editorial:
Current Immunology Reviews (Discontinued) Cerebrovascular Complications of Diabetes: Focus on Stroke
Endocrine, Metabolic & Immune Disorders - Drug Targets Pentraxin 3 Serum Levels in Celiac Patients: Evidences and Perspectives
Recent Patents on Food, Nutrition & Agriculture The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases
Current Drug Targets Anesthetic Cardioprotection in Relation to Mitochondria: Basic Science
Current Pharmaceutical Design Chronic Urticaria: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Unusual Clinical Manifestations of the Antiphospholipid Syndrome
Current Rheumatology Reviews Correlation Analysis of Capillary APOE, VEGF and eNOS Expression in Alzheimer Brains
Current Alzheimer Research Rheumatoid Nodules and Lung
Current Respiratory Medicine Reviews Diversity of Human Immune System Multigene Families and its Implication in the Genetic Background of Rheumatic Diseases
Current Medicinal Chemistry Novel Adjunctive Therapies for the Treatment of Tuberculosis
Current Molecular Medicine Targeting Potassium Channels: New Advances in Cardiovascular Therapy
Recent Patents on Cardiovascular Drug Discovery The Lung in Immune-Mediated Disorder: Rheumatoid Arthritis
Current Drug Targets - Inflammation & Allergy COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews Therapeutic Potential of Targeting Protease Activated Receptors in Cardiovascular Diseases
Current Pharmaceutical Design Arterial Ischemic Stroke in Neonates and Children: Review and Current Issues
Current Pediatric Reviews